Folate binding protein: therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin

Rachel L. Merzel, Sarah M. Boutom, Junjie Chen, Carolina Frey, Kerby Shedden, E. Neil G. Marsh, Mark M. Banaszak Holl

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Blood serum proteins play a critical role in the transport, biodistribution, and efficacy of systemically-delivered therapeutics. Here, we have investigated the concentration- and ligand-dependent aggregation of folate binding protein (FBP), focusing in particular on folic acid, an important vitamin and targeting agent; methotrexate, an antifolate drug used to treat cancer and rheumatoid arthritis; and leucovorin which is used to decrease methotrexate toxicity. We employed atomic force microscopy to characterize, on a particle-by-particle basis, the volumes of the FBP nanoparticles that form upon ligand binding. We measured the distribution of FBP nanoparticle volumes as a function of ligand concentration over physiologically- and therapeutically-relevant ranges. At physiologically-relevant concentrations, significant differences in particle volume distributions exist that we hypothesize are consistent with different trafficking mechanisms for folic acid and methotrexate. In addition, we hypothesize leucovorin is trafficked and delivered like folic acid at therapeutically-relevant concentrations. We propose that changes in dosing procedures could improve the delivery and therapeutic index for methotrexate and other folic acid-targeted drug conjugates and imaging agents. Specifically, we suggest pre-binding the drugs to FBP may provide a better formulation for drug delivery of methotrexate for both cancer and rheumatoid arthritis. This would be analogous to pre-binding paclitaxel to albumin, which is already used in the clinic.

Original languageEnglish
Pages (from-to)2603-2615
Number of pages13
JournalNanoscale
Volume9
Issue number7
DOIs
Publication statusPublished - 21 Feb 2017
Externally publishedYes

Cite this

Merzel, Rachel L. ; Boutom, Sarah M. ; Chen, Junjie ; Frey, Carolina ; Shedden, Kerby ; Marsh, E. Neil G. ; Banaszak Holl, Mark M. / Folate binding protein : therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin. In: Nanoscale. 2017 ; Vol. 9, No. 7. pp. 2603-2615.
@article{558641ee68214ccd8386c7a7bd437584,
title = "Folate binding protein: therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin",
abstract = "Blood serum proteins play a critical role in the transport, biodistribution, and efficacy of systemically-delivered therapeutics. Here, we have investigated the concentration- and ligand-dependent aggregation of folate binding protein (FBP), focusing in particular on folic acid, an important vitamin and targeting agent; methotrexate, an antifolate drug used to treat cancer and rheumatoid arthritis; and leucovorin which is used to decrease methotrexate toxicity. We employed atomic force microscopy to characterize, on a particle-by-particle basis, the volumes of the FBP nanoparticles that form upon ligand binding. We measured the distribution of FBP nanoparticle volumes as a function of ligand concentration over physiologically- and therapeutically-relevant ranges. At physiologically-relevant concentrations, significant differences in particle volume distributions exist that we hypothesize are consistent with different trafficking mechanisms for folic acid and methotrexate. In addition, we hypothesize leucovorin is trafficked and delivered like folic acid at therapeutically-relevant concentrations. We propose that changes in dosing procedures could improve the delivery and therapeutic index for methotrexate and other folic acid-targeted drug conjugates and imaging agents. Specifically, we suggest pre-binding the drugs to FBP may provide a better formulation for drug delivery of methotrexate for both cancer and rheumatoid arthritis. This would be analogous to pre-binding paclitaxel to albumin, which is already used in the clinic.",
author = "Merzel, {Rachel L.} and Boutom, {Sarah M.} and Junjie Chen and Carolina Frey and Kerby Shedden and Marsh, {E. Neil G.} and {Banaszak Holl}, {Mark M.}",
year = "2017",
month = "2",
day = "21",
doi = "10.1039/c6nr09060e",
language = "English",
volume = "9",
pages = "2603--2615",
journal = "Nanoscale",
issn = "2040-3364",
publisher = "The Royal Society of Chemistry",
number = "7",

}

Folate binding protein : therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin. / Merzel, Rachel L.; Boutom, Sarah M.; Chen, Junjie; Frey, Carolina; Shedden, Kerby; Marsh, E. Neil G.; Banaszak Holl, Mark M.

In: Nanoscale, Vol. 9, No. 7, 21.02.2017, p. 2603-2615.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Folate binding protein

T2 - therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin

AU - Merzel, Rachel L.

AU - Boutom, Sarah M.

AU - Chen, Junjie

AU - Frey, Carolina

AU - Shedden, Kerby

AU - Marsh, E. Neil G.

AU - Banaszak Holl, Mark M.

PY - 2017/2/21

Y1 - 2017/2/21

N2 - Blood serum proteins play a critical role in the transport, biodistribution, and efficacy of systemically-delivered therapeutics. Here, we have investigated the concentration- and ligand-dependent aggregation of folate binding protein (FBP), focusing in particular on folic acid, an important vitamin and targeting agent; methotrexate, an antifolate drug used to treat cancer and rheumatoid arthritis; and leucovorin which is used to decrease methotrexate toxicity. We employed atomic force microscopy to characterize, on a particle-by-particle basis, the volumes of the FBP nanoparticles that form upon ligand binding. We measured the distribution of FBP nanoparticle volumes as a function of ligand concentration over physiologically- and therapeutically-relevant ranges. At physiologically-relevant concentrations, significant differences in particle volume distributions exist that we hypothesize are consistent with different trafficking mechanisms for folic acid and methotrexate. In addition, we hypothesize leucovorin is trafficked and delivered like folic acid at therapeutically-relevant concentrations. We propose that changes in dosing procedures could improve the delivery and therapeutic index for methotrexate and other folic acid-targeted drug conjugates and imaging agents. Specifically, we suggest pre-binding the drugs to FBP may provide a better formulation for drug delivery of methotrexate for both cancer and rheumatoid arthritis. This would be analogous to pre-binding paclitaxel to albumin, which is already used in the clinic.

AB - Blood serum proteins play a critical role in the transport, biodistribution, and efficacy of systemically-delivered therapeutics. Here, we have investigated the concentration- and ligand-dependent aggregation of folate binding protein (FBP), focusing in particular on folic acid, an important vitamin and targeting agent; methotrexate, an antifolate drug used to treat cancer and rheumatoid arthritis; and leucovorin which is used to decrease methotrexate toxicity. We employed atomic force microscopy to characterize, on a particle-by-particle basis, the volumes of the FBP nanoparticles that form upon ligand binding. We measured the distribution of FBP nanoparticle volumes as a function of ligand concentration over physiologically- and therapeutically-relevant ranges. At physiologically-relevant concentrations, significant differences in particle volume distributions exist that we hypothesize are consistent with different trafficking mechanisms for folic acid and methotrexate. In addition, we hypothesize leucovorin is trafficked and delivered like folic acid at therapeutically-relevant concentrations. We propose that changes in dosing procedures could improve the delivery and therapeutic index for methotrexate and other folic acid-targeted drug conjugates and imaging agents. Specifically, we suggest pre-binding the drugs to FBP may provide a better formulation for drug delivery of methotrexate for both cancer and rheumatoid arthritis. This would be analogous to pre-binding paclitaxel to albumin, which is already used in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=85013188369&partnerID=8YFLogxK

U2 - 10.1039/c6nr09060e

DO - 10.1039/c6nr09060e

M3 - Article

VL - 9

SP - 2603

EP - 2615

JO - Nanoscale

JF - Nanoscale

SN - 2040-3364

IS - 7

ER -

Merzel RL, Boutom SM, Chen J, Frey C, Shedden K, Marsh ENG et al. Folate binding protein: therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin. Nanoscale. 2017 Feb 21;9(7):2603-2615. https://doi.org/10.1039/c6nr09060e